Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC50 and MEC90 of ropivacaine for ultrasound-guided median nerve block in pediatric trigger finger surgery
ChiCTR2100045215Phase 4Recruiting
- Sponsor
- Children's Hospital of Chongqing Medical University
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ropivacaine in trigger finger, sponsored by Children's Hospital of Chongqing Medical University. Primary endpoints: Half effective concentration (EC50) of ropivacaine for median nerve block and 90% minimum effective concentration (MEC90) of ropivacaine for median nerve block. Started Apr 2021; status: recruiting.
02
Drugs
ropivacaine
03
Conditions
trigger finger
Beyond the preview
Go deeper on ChiCTR2100045215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045215.